Brand Name
XYWAV
Generic Name
oxybates
View Brand Information FDA approval date: November 02, 2020
Classification: Central Nervous System Depressant
Form: Solution
What is XYWAV (oxybates)?
XYWAV is a central nervous system depressant indicated for the treatment of: Cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Safety, Convenience, and Tolerability of a Nightly Single Oral Dose of Extended-release Sodium Oxybate in Children
Summary: The main objectives of this study are to determine the treatment preferences of children with narcolepsy type 1 between Extended-release sodium oxybate and Non-extended-release oxybates (Sodium oxybate or a medication with the combination of Calcium, magnesium, potassium, and sodium oxybates). The study will also assess the safety, convenience, and tolerability of Extended-release sodium oxybate. ...